Stay connected with the latest developments in FSHD research and community progress. This is your trusted hub for updates on scientific breakthroughs, inspiring personal stories, and the work we’re doing globally to accelerate treatments and a cure for Facioscapulohumeral Muscular Dystrophy (FSHD).
By staying informed and engaged, you’re helping us raise awareness, support individuals and families impacted by FSHD, and drive real momentum toward lasting solutions.
Official Match Day Partnership to inspire packed Accor stadium to ‘Use Your Muscles for Those Who Can’t’ FSHD Global
FSHD1 TESTING, PATHWEST LABORATORY MEDICINE WA PathWest has been undertaking assay testing for FSHD1 since 2022, following thegenerous donation of
ARM-201 has completed preclinical studies and successful pre-IND engagement with the U.S. Food and Drug Administration (FDA) and has received both Orphan Drug and Rare Paediatric Disease designations. They are now scaling for clinical studies.
FSHD Global Research Foundation in Sydney is excited to announce it has invested in miRecule’s second generation drug development program
FSHD Global’s own Emma Weatherley was featured on an episode of Radio National Breakfast where she shared her personal story
SEOUL, South Korea, July 06, 2026 (GLOBE NEWSWIRE) — NovMetaPharma Co., Ltd. (“NovMetaPharma” or “NMP”), a clinical-stage biopharmaceutical company that
We publish a monthly newsletter to keep the FSHD community informed, connected, and inspired. If there’s a story you’d like to tell, a question you’d like answered, or a topic you think we should explore, we’d love to hear from you.
Send an email to admin@fshdglobal.org.
